Microfluidically fabricated self-oxygen-supplied DL-86 lipid nanoplatform for in vitro synergistic photodynamic/photothermal dual phototherapy against hypoxia-tolerant glioblastoma
5 affiliations
- 1Central Laboratory of YunFu People’s Hospital, YunFu Key Laboratory of Brain Diseases Research, YunFu People’s Hospital, Guangdong 527300 Yunfu, China
- 2Guangzhou University of Chinese Medicine, 510006 Guangzhou, China
- 3Department of Biology, Faculty of Arts and Sciences, Beijing Normal University, 519087 Zhuhai, China
- 4School of Pharmacy, Mudanjiang Medical University, 157011 Mudanjiang, China
- 5Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Victoria Parkville, Australia
Abstract
Glioblastoma (GBM) bears sustained intratumoral hypoxia that blocks oxygen-dependent photodynamic therapy (PDT). Hypoxia suppresses Type II photochemical reactions and singlet oxygen (¹O₂) generation, while oxygen-free photothermal therapy (PTT) can complement PDT for synergistic tumor suppression. Copper phthalocyanine DL-86 is a single NIR dual-responsive photosensitizer capable of simultaneous ROS and heat production, yet its anti-tumor potency is limited by tumor hypoxia and poor cellular uptake. Herein, microfluidics was adopted to fabricate self-oxygenated liposomes DL-86@CAT@Lip co-loaded with DL-86 and catalase (CAT). The uniform spherical nanoparticles (114.7 nm) exhibited excellent colloidal and serum stability. Encapsulated CAT decomposed intracellular H₂O₂ to relieve hypoxia, and the nanosystem achieved a photothermal conversion efficiency of 46.15%. Under 660 nm laser irradiation, combined PDT/PTT drastically reduced hypoxic C6 glioma cell viability to ~20.3%. Hemolysis tests confirmed favorable intravenous hemocompatibility. This work first proves that the self-oxygenation liposomal platform enhances hypoxic anti-GBM dual phototherapy, supplying an in vitro concept and a blueprint for brain tumor phototherapeutic nanomedicines.
Related
- Tumor Microenvironment-Triggered Dual-Prodrug Nanoplatform for Augmented Photodynamic Therapy: Self-Quenched Photosensitizer Activation and Nitric Oxide-Mediated Sensitization
- Low‐Density Lipoprotein Receptor‐Targeted Biomimetic Nanoplatform Suppresses Glioblastoma Stemness and Remodels Antitumor Immunity via Dual Metabolic Disruption
- Fe-doped polydopamine pickering emulsion as a nanoplatform for synergistic photothermal-ferroptosis immunotherapy in breast cancer
- A berberine-functionalized green silver nanoplatform for combined chemo-photodynamic therapy against breast cancer cells
- Hybrid Nanocrystalline Theranostic Agents Designed for Magnetic Resonance Imaging, Photothermal, and Photodynamic Therapies Against Cancer
BibTeX
@article{gong2026microfluidically,
title = {{Microfluidically fabricated self-oxygen-supplied DL-86 lipid nanoplatform for in vitro synergistic photodynamic/photothermal dual phototherapy against hypoxia-tolerant glioblastoma}},
author = {Jun Gong and Xiaoming Pan and Shichao Wang and Yifan Liu and Guangwei Wang and Min Yu and Pu Chun Ke and Mengze Xu},
journal = {Discover Nano},
year = {2026},
month = oct,
doi = {10.1186/s11671-026-05081-9},
url = {https://doi.org/10.1186/s11671-026-05081-9},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Microfluidically fabricated self-oxygen-supplied DL-86 lipid nanoplatform for in vitro synergistic photodynamic/photothermal dual phototherapy against hypoxia-tolerant glioblastoma
AU - Jun Gong
AU - Xiaoming Pan
AU - Shichao Wang
AU - Yifan Liu
AU - Guangwei Wang
AU - Min Yu
AU - Pu Chun Ke
AU - Mengze Xu
PY - 2026
DA - 2026/10/27
JO - Discover Nano
DO - 10.1186/s11671-026-05081-9
UR - https://doi.org/10.1186/s11671-026-05081-9
AB - Glioblastoma (GBM) bears sustained intratumoral hypoxia that blocks oxygen-dependent photodynamic therapy (PDT). Hypoxia suppresses Type II photochemical reactions and singlet oxygen (¹O₂) generation, while oxygen-free photothermal therapy (PTT) can complement PDT for synergistic tumor suppression. Copper phthalocyanine DL-86 is a single NIR dual-responsive photosensitizer capable of simultaneous ROS and heat production, yet its anti-tumor potency is limited by tumor hypoxia and poor cellular uptake. Herein, microfluidics was adopted to fabricate self-oxygenated liposomes DL-86@CAT@Lip co-loaded with DL-86 and catalase (CAT). The uniform spherical nanoparticles (114.7 nm) exhibited excellent colloidal and serum stability. Encapsulated CAT decomposed intracellular H₂O₂ to relieve hypoxia, and the nanosystem achieved a photothermal conversion efficiency of 46.15%. Under 660 nm laser irradiation, combined PDT/PTT drastically reduced hypoxic C6 glioma cell viability to ~20.3%. Hemolysis tests confirmed favorable intravenous hemocompatibility. This work first proves that the self-oxygenation liposomal platform enhances hypoxic anti-GBM dual phototherapy, supplying an in vitro concept and a blueprint for brain tumor phototherapeutic nanomedicines.
SN - 2731-9229
ER -